Hajtovic Sabastian, LoPresti Melissa A, Zhang Lu, Katlowitz Kalman A, Kizek Dominic J, Lam Sandi
1Sophie Davis Biomedical Education Program, City College of New York, City University of New York School of Medicine, New York, New York.
2Department of Neurosurgery, Division of Pediatric Neurosurgery, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas; and.
J Neurosurg Pediatr. 2022 Mar 18;29(6):667-680. doi: 10.3171/2022.1.PEDS222. Print 2022 Jun 1.
Drug-resistant epilepsy (DRE) affects many children. Vagus nerve stimulation (VNS) may improve seizure control; however, its role in children with genetic etiologies of epilepsy is not well described. The authors systematically reviewed the literature to examine the effectiveness of VNS in this cohort.
In January 2021, the authors performed a systematic review of the PubMed/MEDLINE, SCOPUS/Embase, Cochrane, and Web of Science databases to investigate the impact of VNS on seizure outcomes in children with genetic etiologies of epilepsy. Primary outcomes included seizure freedom rate, ≥ 90% seizure reduction rate, and ≥ 50% seizure reduction rate. Secondary outcomes were seizure severity and quality of life (QOL), including cognitive, functional, and behavioral outcomes. A random-effects meta-analysis was performed.
The authors identified 125 articles, of which 47 with 216 nonduplicate patients were analyzed. Common diagnoses were Dravet syndrome (DS) (92/216 patients [42.6%]) and tuberous sclerosis complex (TSC) (63/216 [29.2%]). Seizure freedom was not reported in any patient with DS; the pooled proportion (95% CI) of patients with ≥ 50% seizure reduction was 41% (21%-58%). Secondary cognitive outcomes of VNS were variable in DS patients, but these patients demonstrated benefits in seizure duration and status epilepticus. In TSC patients, the pooled (95% CI) seizure freedom rate was 40% (12%-71%), ≥ 90% seizure reduction rate was 31% (8%-56%), and ≥ 50% reduction rate was 68% (48%-91%). Regarding the secondary outcomes of VNS in TSC patients, several studies reported decreased seizure severity and improved QOL outcomes. There was limited evidence regarding the use of VNS to treat patients with other genetic etiologies of epilepsy, such as mitochondrial disease, Rett syndrome, Doose syndrome, Landau-Kleffner syndrome, Aicardi syndrome, Angelman syndrome, ring chromosome 20 syndrome, and lissencephaly; variable responses were reported in a limited number of cases.
The authors conducted a systematic review of VNS outcomes in children with genetic etiologies of DRE. Among the most studied conditions, patients with TSC had substantial seizure reduction and improvements in QOL, whereas those with DS had less robust seizure reduction. Increased testing, diagnosis, and long-term follow-up studies are necessary to better characterize VNS response in these children.
耐药性癫痫(DRE)影响许多儿童。迷走神经刺激(VNS)可能改善癫痫发作的控制;然而,其在具有遗传性癫痫病因的儿童中的作用尚未得到充分描述。作者系统回顾了文献,以研究VNS在该队列中的有效性。
2021年1月,作者对PubMed/MEDLINE、SCOPUS/Embase、Cochrane和Web of Science数据库进行了系统回顾,以调查VNS对具有遗传性癫痫病因的儿童癫痫发作结局的影响。主要结局包括无癫痫发作率、癫痫发作减少≥90%的比例和癫痫发作减少≥50%的比例。次要结局是癫痫发作严重程度和生活质量(QOL),包括认知、功能和行为结局。进行了随机效应荟萃分析。
作者识别出125篇文章,其中47篇涉及216例无重复患者的文章被分析。常见诊断为德雷维特综合征(DS)(92/216例患者[42.6%])和结节性硬化症(TSC)(63/216例[29.2%])。没有DS患者实现无癫痫发作的报告;癫痫发作减少≥50%的患者的合并比例(95%CI)为41%(21%-58%)。VNS的次要认知结局在DS患者中各不相同,但这些患者在癫痫发作持续时间和癫痫持续状态方面表现出益处。在TSC患者中,合并(95%CI)无癫痫发作率为40%(12%-71%),癫痫发作减少≥90%的比例为31%(8%-56%),癫痫发作减少≥50%的比例为68%(48%-91%)。关于VNS在TSC患者中的次要结局,多项研究报告癫痫发作严重程度降低和QOL结局改善。关于使用VNS治疗其他遗传性癫痫病因患者的证据有限,如线粒体疾病、雷特综合征、杜斯综合征、兰道-克莱夫纳综合征、艾卡迪综合征、天使综合征、20号环状染色体综合征和无脑回畸形;在少数病例中报告了不同的反应。
作者对具有遗传性DRE病因的儿童VNS结局进行了系统回顾。在研究最多的疾病中,TSC患者的癫痫发作显著减少且QOL改善,而DS患者的癫痫发作减少效果较差。需要增加检测、诊断和长期随访研究,以更好地描述这些儿童对VNS的反应。